Bio-Rad Laboratories, Inc. (NYSE:BIO) Stock Holdings Trimmed by WFA of San Diego LLC

WFA of San Diego LLC lowered its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 5.0% during the 1st quarter, Holdings Channel reports. The fund owned 1,420 shares of the medical research company’s stock after selling 75 shares during the period. WFA of San Diego LLC’s holdings in Bio-Rad Laboratories were worth $800,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in the business. Tobam increased its position in shares of Bio-Rad Laboratories by 36.1% during the 1st quarter. Tobam now owns 98 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 26 shares during the period. Pendal Group Ltd acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at $617,000. Assenagon Asset Management S.A. increased its position in shares of Bio-Rad Laboratories by 55.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 21,759 shares of the medical research company’s stock valued at $12,255,000 after purchasing an additional 7,791 shares during the period. Strs Ohio increased its position in shares of Bio-Rad Laboratories by 44.6% during the 1st quarter. Strs Ohio now owns 6,091 shares of the medical research company’s stock valued at $3,430,000 after purchasing an additional 1,879 shares during the period. Finally, Empirical Finance LLC increased its position in shares of Bio-Rad Laboratories by 14.4% during the 1st quarter. Empirical Finance LLC now owns 358 shares of the medical research company’s stock valued at $202,000 after purchasing an additional 45 shares during the period. 63.66% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently issued reports on BIO shares. TheStreet cut Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a research report on Thursday, April 28th. Jefferies Financial Group reiterated a “buy” rating and set a $700.00 price target on shares of Bio-Rad Laboratories in a research report on Friday, April 29th. Citigroup decreased their target price on Bio-Rad Laboratories from $800.00 to $750.00 in a report on Monday, May 2nd. Finally, StockNews.com initiated coverage on Bio-Rad Laboratories in a report on Thursday, March 31st. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $793.33.

Shares of NYSE BIO opened at $509.67 on Thursday. The company has a quick ratio of 4.16, a current ratio of 5.10 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $15.26 billion, a price-to-earnings ratio of -104.44 and a beta of 0.93. The stock’s fifty day simple moving average is $506.20 and its 200 day simple moving average is $573.10. Bio-Rad Laboratories, Inc. has a 52-week low of $462.61 and a 52-week high of $832.70.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The medical research company reported $4.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.80 by $2.14. Bio-Rad Laboratories had a positive return on equity of 3.66% and a negative net margin of 3.49%. The business had revenue of $700.10 million for the quarter, compared to the consensus estimate of $678.00 million. During the same quarter in the previous year, the company posted $5.21 earnings per share. Bio-Rad Laboratories’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.2 earnings per share for the current year.

About Bio-Rad Laboratories (Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Featured Articles

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.